// App-Quantinova.ai

14307 : Reduction in the Risk of Major Adverse Cardiovascular Events With Apabetalone, a Bet Protein Inhibitor, in Patients With Recent Acute Coronary Syndrome and Type 2 Diabetes According to Insulin Treatment: Analysis of the Betonmace Trial

Researchers

Presenter

  • Gregory G Schwartz

Principal Investigators

  • Stephen J Nicholls

  • Henry Ginsberg

  • Jan JOHANSSON

  • Kamyar Kalantar-Zadeh

  • Ewelina Kulikowski

  • Peter P Toth

  • Norman Wong

  • Michael Sweeney

  • Kausik K Ray

Medical Centers

  • Radiology, Univ of Colorado Sch of Medicine, Aurora, CO

  • Deakin University, Melbourne, Australia

  • Columbia University, New York, NY

  • RESVERLOGIX, San Ramon, CA

  • University of California, Irvine, Fullerton, CA

  • RESVERLOGIX CORP, Calgary, Canada

  • CGH Med Cntr, Rock Falls, IL

  • Resverlogix Corp., Calgary, Canada

  • IMPERIAL COLLEGE, London, United Kingdom

Locations

  • United States

  • Australia

  • Canada

  • United Kingdom

Companies

  • N/A

Study Components

Therapeutic Area

  • Endocrine/metabolic Diseases (ME)

Disease

  • Acute Coronary Syndromes

  • Type 2 diabetes mellitus

  • Diabetes

Biomarkers

  • Nucleoside diphosphate kinase A

  • Insulin

Drug/Treatment

  • RVX-208

Outcome

  • N/A

Study Design

  • N/A

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved